I would say Trofinetide definitely moves the needle for ACADIA but not nearly as much as NUPLAZID and new indications for Pimavanserin.
The accessible market for Parkinson’s, dementia and possibly Schizophrenia (the last 2 in the pipeline) far outweighs Trofinetide. BUT Trofinetide offers them the opportunity to derisk/diversify from their heavy reliance on Pimavanserin. It was questions over that drug by the FDA that recently put ACADIA shareprice into the toilet..
So I am pretty sure ACADIA is keen to see returns on their US150M+ investment in Trofinetide as soon as possible as is ACADIAs shareholders..
My opinion only. Not investment advice.
- Forums
- ASX - By Stock
- ACADIA & NEU charts YTD
I would say Trofinetide definitely moves the needle for ACADIA...
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.30 |
Change
-0.200(1.03%) |
Mkt cap ! $2.466B |
Open | High | Low | Value | Volume |
$19.50 | $19.59 | $19.11 | $5.729M | 296.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 259 | $19.28 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.31 | 640 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17 | 20.260 |
1 | 17 | 20.090 |
1 | 50 | 19.600 |
1 | 100 | 19.500 |
1 | 1 | 19.490 |
Price($) | Vol. | No. |
---|---|---|
19.390 | 2 | 1 |
19.470 | 1 | 1 |
19.590 | 250 | 1 |
19.600 | 360 | 2 |
19.630 | 154 | 1 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online